External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

Key points (machine generated)<ul><li>Harrow is a pharmaceutical company specializing in prescription medications for ophthalmologists and optometrists.</li><li>The company offers FDA-approved branded ophthalmic pharmaceuticals and innovative compounded prescription medicines.</li><li>Harrow owns commercial rights to ten branded ophthalmic pharmaceutical products and operates ImprimisRx, a pharmaceutical-compounding business.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Harrow is a pharmaceutical company specializing in prescription medications for ophthalmologists and optometrists.The company offers FDA-approved branded ophthalmic pharmaceuticals and innovative compounded prescription medicines.Harrow owns commercial rights to ten branded ophthalmic pharmaceutical products and operates ImprimisRx, a pharmaceutical-compounding business.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Harrow Inc (HROW) - Tuesday, Oct 31, 2023

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/santen-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:8602:1" rel="noopener">Santen Pharmaceutical (4536 JP)</a> expects generic competition for mainstay product in Japan in FY24, while overseas business should continue stable growth. The company guided for FY24 revenue of ¥273B (-2%).</li>
<li>Due to the absence of impairment loss, Santen is expected to report operating profit of ¥32B in FY24 from an operating loss of ¥3B in FY23.</li>
<li>Santen has unveiled new medium-term management plan, which calls for revenue of ¥280B, core operating profit of ¥56B, core ROE ratio of 13%, and core EPS growth rate of 10%+.</li>
</ul>



Santen Pharmaceutical (4536 JP) expects generic competition for mainstay product in Japan in FY24, while overseas business should continue stable growth. The company guided for FY24 revenue of ¥273B (-2%).
Due to the absence of impairment loss, Santen is expected to report operating profit of ¥32B in FY24 from an operating loss of ¥3B in FY23.
Santen has unveiled new medium-term management plan, which calls for revenue of ¥280B, core operating profit of ¥56B, core ROE ratio of 13%, and core EPS growth rate of 10%+.


Santen Pharmaceutical (4536 JP): Aims to Ride Patent Cliff Through Focus on Improving Profitability

United States

Harrow Health, Inc. operates as a pharmaceutical company. The Company specializes in development, production, and sale of medications for treatment of various diseases. Harrow Health operates in the State of California.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Harrow Health (HROW US)

Harrow Inc (HROW) - Tuesday, Oct 31, 2023

Harrow owns commercial rights to ten branded ophthalmic pharmaceutical products and operates ImprimisRx, a pharmaceutical-compounding business.

Value Investors Club

Santen Pharmaceutical (4536 JP): Aims to Ride Patent Cliff Through Focus on Improving Profitability

Despite mainstay products losing patent protection, Santen targets core operating profit margin of 20% in FY26 (from 16% in FY23) through...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)